BOULDER, CO / ACCESS Newswire / March 18, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized ...
NAPLES, FL / ACCESS Newswire / March 18, 2026 / Stemtech Corporation, the global leader and pioneer in stem cell nutrition, ...
ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pillApproval supported by four phase 3 studies that met ...
Black Book Research names IKS Health a top-performing vendor in AI-Driven RCM Managed Services, Managed Medical Coding Services, and Clinical Documentation & AI Services. NEW YORK CITY, NY / ACCESS ...
Partnership will validate high quality, species-specific Ankyron binders for key animal health science applications, including prevention and monitoring of zoonotic diseasesOXFORD, England & EDINBURGH ...
Comprehensive analysis of one of the largest datasets with harmonized variant calls from over 8,000 cancer whole genomes enables researchers worldwide to uncover rare drivers, new targets, and ...
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, PA / ACCESS ...
Collaboration with one of the world's largest animal health companies expected to accelerate TRUFORMA adoption, expand installed base, and drive recurring diagnostic revenue ANN ARBOR, MI / ACCESS ...
Collaboration expands access to accelerator programs, capital networks and industry networks for life science and medtech companies statewideSAN DIEGO & NEWPORT BEACH, Calif.--(BUSINESS ...
HOHCells launches FreezOpt™, a new cryopreservation consumable device designed to improve consistency in biological research ...
US alliance to accelerate next‑generation oral monoclonal antibody therapiesLiège, Belgium, and Roanoke (VA), USA, March 18, 2026 — Bio‑Sourcing SA (‘Bio-Sourcing’) and The Tiny Cargo Company (‘Tiny ...
CTA/IND-enabling studies progress, supported by regulatory interactions with FDA and EMA since Q3 2025, and on track for CTA submission in H1 2026SENS-501 Audiogene trial ongoing; six-month efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results